The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

BGB324 With Pembrolizumab or Dabrafenib/Trametinib in Melanoma

Oddbjørn Straume, MD, PhD
Published Online:9:11 PM, Thu April 20, 2017

Oddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.